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I n t r o d u c t i o n.  Peripheral primitive neuroectodermal tumour (PNET) and extraosseous Ewing’s sarcoma (EES) are
rare paediatric malignancies, which, clinically, are regarded as partially chemosensitive neoplasms.
M a t e r i a l  a n d  m e t h o d s.  We performed a retrospective analysis of clinical data collected in the coordinating centre. All
patients were under the age of 19 and presented with PNET (36 cases) or EES (8 cases). They were treated according to the
CWS-91, SIOP-MMT-91 or CWS-96 protocols. The primary tumour was localized within the head/neck region in 8 cases
(18.2%), in 11 cases (25%) within the chest wall, in 3 cases (6.8%) in the abdomen, in 8 cases (18.2%) paraspinally, in 5
cases (11.4%) within the pelvis, and in 9 cases (20.5%) on the extremities. In 10 patients (22.7%) distant metastases were
present at the time of diagnosis.
R e s u l t s.  32 children (72.7%) achieved complete remission with relapse in 16 cases – local failure in 9, distant failure in 3
and mixed in 4 cases. Response to chemotherapy was observed in 83.3% subjects: in 16.7% – complete, in 33.3% – good and
in 33.3% – partial. The remaining 16.7% did not respond to chemotherapy. 5-year event-free survival (EFS) and overall 5-year
survival estimate (OS) for all analysed patients was 0.39±0.08 and 0.44±0.08, respectively. Patients treated according to the
CWS-96 protocol had a slightly better prognosis as compared to children treated according to the CWS-91/SIOP-MMT-91
protocols. Important factors influencing prognosis were gender, disease stage, and tumour localization.
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Introduction
Peripheral primitive neuroectodermal tumour (PNET)
and extraosseous Ewing’s sarcoma (EES) account for
approximately 10% of all paediatric soft tissue sarcomas
[1]. They present as small round cell malignancies of
neural crest origin. The tumor cells typically demonstrate
expression of MIC2 (CD99) and β2 microglobulin,
a presence of neuronal markers (neurospecific enolase
– NSE, S-100 protein, neurofilaments and others), and/or
form Home-Wright rosettes [1, 2]. Previously the two
entities were distinguished basing on immunochemistry
and microspopic examination. If tumour cells presented
with at least two neuronal markers and/or formed Home-
Wright rosettes, the neoplasm was classified as PNET; if
there was no or only one neuronal marker, Ewing’s
sarcoma was diagnosed. Nowadays both tumours are
classified as the Ewing’s family tumours, as it was shown
that they both demonstrate specific chromosomal
aberrations: t(11;22) or t(21;22) with formation of specific
fusion genes, and show several immunohistochemical
reactions typical only for Ewing’s family tumours [1, 3].
Clinically, both tumours are regarded as partially
chemosensitive malignancies [4-7]. The most common
localisations include the trunk, the extremities and the
head and neck. The treatment of Ewing’s family tumours
in children consists of a combination of multi-agent
chemotherapy, radiotherapy and surgical removal of the
primary tumor [4-7]. Although during the last 20 years
a significant improvement of outcome was achieved in
this group of patients the mortality rate remains high.
Below we present a multicenter study demonstrating our
experiences in the diagnosis and treatment of 44 children
and adolescents suffering from Ewing’s family tumours.
Material and methods
Pa t i e n t s  c h a r a c t e r i s t i c s
The analysed data were collected over a decade, beginning with
the year 1991 in institutions collaborating with the Polish
Paediatric Solid Tumours Group. At the time of diagnosis the
patients were under 19 years of age. In all cases we recognised
peripheral primary neuroectodermal tumours or extraosseous
Ewing’s sarcomas. Institutional ethical review and informed
consent were obtained from all patients. The median follow up
was 26 months (range: 4 – 117 months) for all patients and
40 months (range: 4 – 117 months) for surviving patients.
Over the study period (1991-2002) 306 children with soft
tissue sarcomas were registered at the coordinating centre. Of
these 36 (11.8%) presented with PNET and 8 (2.6%) with EES.
Their age ranged from 6 to 210 months (mean: 117.2±66
months, median: 124.5 months); 21 subjects (47.7%) were below
the age of 10, and 23 (52.3%) were older than 10 years. No
gender predominance was observed: there were 22 boys (50%)
and 22 girls (50%). Detailed patient characteristics have been
presented in Table I.
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C o n c l u s i o n s.  Tumours localized within the abdomen and the extremities, as well as the presence of distant metastases, are
important unfavorable prognostic indicators. Radiotherapy and radical surgery supporting intensive chemotherapy could reduce
the risk of relapse.
Rodzina guzów Ewinga w obr´bie tkanek mi´kkich u dzieci:
11-letnie doÊwiadczenie Polskiej Pediatrycznej Grupy Guzów Litych
W p r o w a d z e n i e.  Obwodowy pierwotny guz neuroektodermalny oraz pozakostny mi´sak Ewinga nale˝à do rzadkich
z∏oÊliwych nowotworów u dzieci. Klinicznie guzy traktowane te sà jako cz´Êciowo wra˝liwe na chemioterapi´.
M a t e r i a ∏  i m e t o d a.  W pracy dokonano retrospektywnej analizy danych klinicznych pacjentów zg∏oszonych do oÊrodka
koordynujàcego. Wszyscy pacjenci byli w wieku poni˝ej 19 lat i u wszystkich rozpoznano obwodowy pierwotny guz
neuroektodermalny lub pozakostnego mi´saka Ewinga. Leczenie by∏o przeprowadzone w oparciu o nast´pujàce protoko∏y
lecznicze: CWS-91, SIOP-MMT-91 lub CWS-96. U 36 osób rozpoznano PNET, natomiast u 8 EES. Guz pierwotny
zlokalizowany by∏ u 8 pacjentów (18,2%) w obr´bie g∏owy/szyi, u 11 (25%) w zakresie Êciany klatki piersiowej, u 3 (6,8%)
w jamie brzusznej, u 8 (18,2%) przyrdzeniowo, u 5 (11,4%) w miednicy, i u 9 (20,5%) w obr´bie koƒczyn. U 10 dzieci (22,7%)
w momencie diagnozy stwierdzono obecnoÊç przerzutów odleg∏ych.
W y n i k i.  32 osoby (72,7%) uzyska∏y ca∏kowità remisj´. WÊród 16 pacjentów, którzy uzyskali pe∏nà remisj´, wystàpi∏ nawrót
choroby: u 9 stwierdzono wznow´ lokalnà, u 3 przerzutowà i u 4 mieszanà. Po pierwszym cyklu chemioterapii, 83,3% guzów
odpowiedzia∏o na zastosowanà chemioterapi´: w 16,7% zaobserwowanà pe∏nà odpowiedê, w 33,3% dobrà i w 33,3%
cz´Êciowà. Pozosta∏e 6,7% guzów nie zareagowa∏o na chemioterapi´. 5-letnie prze˝ycie wolne od choroby (EFS) i ca∏kowite
prze˝ycie (OS) dla wszystkich analizowanych pacjentów wynios∏o odpowiednio 0,39±0,08 i 0.44±0,08. Pacjenci leczeni
zgodnie z protoko∏em CWS-96 charakteryzowali si´ nieznacznie lepszym rokowaniem w stosunku do pacjentów leczonych
wed∏ug protoko∏u CWS-91/SIOP-MMT-91. Czynnikami wp∏ywajàcymi na prze˝ycie by∏y p∏eç, stadium choroby i lokalizacja
ogniska pierwotnego.
W n i o s k i.  Lokalizacja nowotworu w obr´bie jamy brzusznej i koƒczyn, jak równie˝ obecnoÊç przerzutów odleg∏ych by∏y
istotnymi niekorzystnymi parametrami rokowniczymi. Radioterapia i radykalny zabieg chirurgiczny, wspomagajàce
chemioterapi´, mogà obni˝yç ryzyko nawrotu choroby.
Key words: Ewing’s sarcoma, peripheral primary neuroectodermal tumour, outcome, children
S∏owa kluczowe: mi´sak Ewinga, pierwotny obwodowy guz neuroektodermalny, wyniki leczenia, dzieci
Tr e a t m e n t
Over the last decade different modalities were applied in the
treatment of childhood Ewing’s family tumours of soft tissues.
In the early nineties (1991-1995) two protocols were in use:
the CWS-91 protocol (13 patients) for stage I-III [4] and the
SIOP-MMT-89 protocol for stage IV – (2 patients) [5]. From
1996 onward the CWS-96 protocol (29 patients) [6] was used for
all patients (Table I). All these protocols present combinations
of multi-agent chemotherapy, radiotherapy and primary
or/and secondary surgical tumour removal. They all involve
combinations of vincristine, actinomycine D, doxorubicin,
epirubicine, ifosfamide, cyclofosfamide, carboplatine, cis-platin
and etoposide. Combinations of VACA (VCR, ADR, CY,
AMD), EVAIA (VP-16, VCR, ADR, AMD, IFO) and CEVAIE
(CARBO, EPI, IFO, AMD, VCR, VP16) have been adopted in
the CWS protocols and high-dose chemotherapy – Cy/thiotepa
and melphalan/VP-16 with hematopoietic stem cell rescue
or oral maintenance therapy with VP-16/ idarubicin and
trophosphamide have been investigated in metastatic patients.
The intensity, duration and type of chemotherapy were stratified
according to the risk groups defined basing on histology, site
and TNM status. In the CWS-91 subpopulation patients from
group A and B received VACA and patients from group C, i.e.
with poor prognosis – the EVAIA protocol. In the CWS-96
protocol the chemotherapeutic regimen has been risk-adapted
and stratified according to TNM, primary resectability
and histology. Patients in the low risk group received only VCR
and AMD. Standard risk patients were administered VCR,
AMD and IFO (IVA). Patients in the high risk group were
administered CEVAIE – six drug cycles. Radiation was an
effective method of achieving local tumor control in patients
with microscopic or gross residual disease following surgical
resection or chemotherapy. Recomendations for radiation
depended on the primary site and size, histology, age and the
extent of disease before and after surgical resection. Irradiation
was avoided in young children (< 3 years), whenever possible,
because of its adverse effects on growth. According to the
protocols, radiotherapy was commenced during chemotherapy in
the 13th–14th week of treatment (CWS-91) or during the
10th–11th week of treatment (CWS-96). Radiotherapy was
individually considered in small children (below the age of 4)
depending on the response to chemotherapy. The CWS studies
recommended accelerated hyperfractionated irradiation (2x1.6
Gy daily). According to the CWS-91 protocol the patients were
irradiated with 32 Gy/48 Gy and according to the CWS-96 –
with 32 Gy/44.8 Gy. Second-look surgery was stipulated whene-
ver the tumour was considered primarily non-resectable in any
imaging technique: computed tomography (CT) or magnetic
resonance tomography (MRT). None of the patients had been
previously treated for any other malignancy.
Treatment response was evaluated after the first cycle of
chemotherapy in all patients with disease stage III and IV. If
the tumour was not present in any results of imaging diagnostics
(CT, MRT or sonography) and all metastatic lesions cleared,
the patients were assigned to the “complete response” group.
Patients with tumour regression down to 1/3 or less of the initial
tumour volume were classified as “good responders”. Patients
with tumour size of less than 2/3 but more than 1/3 of the
primary tumour volume were assigned to the “partial responding”
group. The group of “non responders” consisted of all patients
with progression or stabilisation of the disease and/or with
tumour regression by less than 1/3 of the initial tumour volume.
Re l a p s e
“Local relapse” was defined as recurrence of the disease at the
site of the primary tumour. Relapse was considered “regional” if
the malignancy appeared in the regional lymph node or “distant”
if it was found in any other localisation. If relapse involved more
than one of groups mentioned above, it was considered a “mixed
relapse”.
S t a t i s t i c a l  a n a l y s i s
Data available by May 2002 was analysed using Statistica® 97 PL
for Windows software. Kaplan-Meier overall survival (OS) was
calculated from the onset of therapy until the latest follow-up or
death from any cause, Kaplan-Meier event-free survival (EFS) –
from the onset of therapy until the time of treatment failure
[8]. Failure was defined as relapse or death from any cause. The
differences between the curves were estimated by F Cox test
and p-values less than 0.05 were considered statistically
significant.
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Table I. Patient characteristics
Characteristic Number of 
patients (%)
Total 44 (100%)
Diagnosis:
– Peripheral primitive neuroectodermal tumour (PNET) 36 (81.8%)
– Extraosseus Ewing’s sarcoma (EES) 8 (18.2%)
Treatment:
– CWS-91 Protocol 13 (29.6%)
– SIOP-MMT-89 Protocol 2 (4.5%)
– CWS-96 Protocol 29 (65.9%)
Age:
– Median value 124.5 months
– <10 age 21 (47.7%)
– ≥10 age 23 (52.3%)
Gender:
– Boys 22 (50%)
– Girls 22 (50%)
Tumour localization:
– Head/neck region 8 (18.2%)
– Chest wall 11 (25%)
– Abdomen 3 (6.8%)
– Paraspinal 8 (18.2%)
– Pelvis 5 (11.4%)
– Extremities 9 (20.5%)
Tumour size
– <5 cm 9 (20.5%)
– ≥5 cm 33 (75%)
– no data 2 (4.5%)
Tumour stage
– II (localized disease, microscopic rests after resection) 7 (15.9%)
– III (localized disease, macroscopic rests after resection) 27 (61.4%)
– IV (distant metastases) 10 (22.7%)
Regional lymph nodes involvement:
– Yes 10 (22.7%)
– No 34 (87.3%)
Metastases localization:
– Lungs 6
– Bones 3
– Non-regional lymph nodes 3
– Liver 2
– Bone marrow 2
– Pleura 1
– Central nervous system 1
– Right upper arm 1
Results
At the time of analysis 23 subjects (52.3%) were still alive.
The detailed outcome analysis according to the disease
stage is presented in Table II. 32 children (72.7%)
achieved complete clinical remission (CCR) after first
line treatment. In 16 individuals, who had achieved CCR
(36.4%) relapse occurred: local relapse in 9 cases
(20.5%), distant relapse in 3 cases (6.8%) and mixed
relapse in 4 cases (9.1%). The remaining 16 (36.4%) pts
are still in 1st CCR. In 4 cases (9.1%) partial remission
was documented while in 8 cases (18.2%) we noted
progression.
Table II. Final outcome according to the stage of disease
Stage II Stage III Stage IV
Surviving patients: 6 12 5
– First complete remission 6 8 2
– Partial remission – 2 1
– Local relapse – 1* 1
– Metastatic relapse – – 1**
– Mixed relapse – 1 –
Deceased patients: 1 15 5
– Partial remission – 1*** –
– Local relapse – 6 1
– Metastatic relapse – 1 1
– Mixed relapse – 2 1
– Progression 1 5 2
* The patient achieved second complete remission
** The patient achieved second complete remission
*** The patient died because of acute brain oedema
After the first cycle of chemotherapy 30 patients
with stage III and IV disease were assessed according to
treatment response. 5 patients (16.7%) responded
completely to the employed treatment, 10 (33.3%) were
classified as good responders, in 10 cases (33.3%) partial
response was observed, and the remaining 5 children
(16.7%) were classified as non-responders. 
Radiotherapy was administered to 31 patients
(70.5%) – the dose range varying from 22.5 to 58 Gy
(mean: 42.2±9.0 Gy). 12 patients received hyper-
fractionated irradiation and 19 subjects – standard
irradiation. The treatment results according to the
administered radiotherapy are presented in the Table III.
The most common reasons for not administering
radiotherapy were: patient age below 4 years or lack
parental consent.
Second-look surgery was performed in 17 children
(38.6%). In 2 children with stage III disease second-look
surgery was limited to biopsy only, which revealed no
residual tumour (histological complete remission), and
in another patient only the metastases were radically
removed, as no residual tumour was discerned on
imaging. All these 3 patients remain in first complete
remission. In 6 patients mutilating resection of the
primary tumour was performed, however only in 2 cases
the resection was radical. 1 patient is still alive and in
complete remission and 1 (in stage IV) died due to
disease progression. In 3 patients microscopic, and in 1
patient macroscopic tumour residue was found; all these
patients died: 2 due to local relapse, 1 due to mixed
relapse and 1 due to rapid disease progression. Another 8
patients underwent non-mutilating surgery, which was
radical only in 3 cases. Unfortunately, all these patients
died: 2 because of local relapse and 1 because of
metastatic relapse. In 3 patients microscopic residuum
was observed (all these patients died) and in 2 cases –
macroscopic residue (one patient is still alive in CCR
and one died due to local relapse).
5-year event-free survival (EFS) and overall 5-year
survival estimate (OS) for all the patients was 0.39±0.08
and 0.44±0.08, respectively. Patients treated according
to the CWS-96 protocol had slightly better prognosis as
compared to children treated according to the CWS-
91/SIOP-MMT-91 protocol (5-year EFS 0.41 and 0.27,
respectively, p=0.03; 5-year OS 0.44 and 0.4, respectively,
p=0.09). Having analysed several clinical parameters we
state that the most important factors influencing
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Table III. Final results of treatment according to the administered radiotherapy
No radiotherapy Standard radiotherapy Hyperfractionated radiotherapy
Surviving patients: 5 10 8
– First complete remission 3 6 7
– Partial remission 2 1 –
– Local relapse – 1 1**
– Metastatic relapse – 1* –
– Mixed relapse – 1 –
Decreased patients: 8 9 4
– Partial remission 1*** – –
– Local relapse – 6 1
– Metastatic relapse 1 1 –
– Mixed relapse – 1 2
– Progression 6 1 1
* The patient achieved second complete remission
** The patient achieved second complete remission
*** The patient died because of acute brain oedema
prognosis are gender (boys vs. girls: 5-year EFS 0.28 and
0.38, respectively, p=0.04; 5-year OS 0.31 and 0.58
respectively, p=0.02), stage of disease (Figure 1), and
tumour localization (Figure 2). The best outcomes were
observed in patients with stage II disease (stage II vs.
stage III: p<0.01; stage II vs. stage IV: p<0.01), and
poorer prognosis was found in patients with stage IV
disease, although the difference between stage IV and
stage III was not statistically significant (p=0.47)
(Figure 1). When comparing different tumour locali-
zations the best survival ratio was found in the case of
tumours located within the pelvis and paraspinally. Very
poor outcome was observed in patients with neoplasms
within the abdomen and the extremities – in the case of
these localisations we did not observe survivals exceeding
5 years (Figure 2). We observed no impact on survival of
such parameters as: age (<10 years vs. >10 years,
p=0.42), diagnosis (EES vs. PNET, p=0.51), tumour size
(<5 cm vs. >5 cm, p=0.38) and regional lymph node
involvement (involved vs. non-involved, p=0.92).
As for response to the 1st chemotherapy cycle –
better outcomes were observed in the case of children
showing complete response or regression of over 2/3 of
the tumour, as compared to patients who responded only
partially or were classified as non-responders although
the difference was not significant (Figure 3). In 7 patients
with disease stage III and IV we had insufficient data to
evaluate the response after the 1st cycle of chemotherapy.
Radiotherapy had significant influence on the final results
of therapy (Table III, Figure 4). Patients treated with any
kind of radiotherapy presented with a significantly better
survival ratio as compared to patients who did not receive
any irradiation (p<0.05; Figure 4). Although there was no
significant difference in the survival of patients who had
undergone hyperfractionated and standard radiotherapy,
it seems that hyperfractionated irradiation could be more
profitable, as in this group the relapses were less common:
4 subjects (33.3%), as compared to 11 patients (57.9%) in
standard radiotherapy group (Table III).
Discussion
Ewing’s family tumours of soft tissue are rare childhood
malignancies (the incidence in Poland is estimated at
approximately 4-5 new cases per year). Therefore only
the cooperation of many paediatric and oncological
centres allows to perform a reliable analysis of patient
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Figure 1. Overall survival according to disease stage
Figure 2. Overall survival according to primary tumour localization
Figure 3. Overall survival according to the response to the 1st
chemotherapy cycle in patients with stage III and IV
Figure 4. Overall survival according to the performed radiotherapy
data. This study is a multicenter analysis of 11 years of
experience of the Polish Pediatric Solid Tumours’ Group,
which, to the best of our knowledge, is the first such an
attempt in Poland.
The characteristics of our patient group are similar
to those previously reported in literature [9-13]. The
tumours are most common in older children and in young
adolescents, although sometimes they occur in very young
patients or even in neonates [12]. There is no gender
predominance. The most common locations are: the chest
wall, the extremities and the head and neck region.
Distant metastases predominantly involve the lungs and
bones. However, it seems that in Polish children and
adolescents the diagnosis was made relatively late, thus
resulting in a more advance patients status. In most
patients primary tumours were over 5 cm (75% in this
study, as compared to 63% in the American group [11]).
Moreover, radical primary resection was not possible in
any patient and thus we enrolled no patients in stage I of
the disease – i.e. in the group with the best survival ratio
[11, 12]. Similarly, the percentage of subjects in stage II
was also lower (16%) than in other studies (23-27%) [11,
12].
The more advanced stage of the disease could result
in the poorer survival ratio of our group (5-year EFS
39% and 5-year OS 44%) as compared to that reported
by other authors (EFS 55-67%, OS 62-77%) [11, 13].
Although the complete remission ratio was high (over
70%) and comparable to that reported in literature, yet
the incidence of relapses (especially local) was very high.
This could be explained by the fact that a relatively large
group of patients (nearly 30%) were not irradiated. We
have clearly demonstrated that radiotherapy is an
important element in the therapy of PNET and EES and
significantly improved prognosis. Our observations are
consistent with those of other authors [11, 14-16].
Interestingly, second-look surgery did not improve local
control; this, in turn, contradicts literature data, according
to which complete surgical excision reduces the risk of
local reccurence, although it does not prevent metastatic
spread [12]. However, in our patient group a majority of
the resections were incomplete – with microscopic, or
even macroscopic, tumour residue. Moreover, the excision
was predominantly performed in patients who showed
poor response to chemotherapy, and therefore were at an
increased risk of progression.
The stage of disease, gender and tumour localization
were the most important factors affecting survival.
Parameters such as tumour size and patient age had no
impact on survival. We found this surprising, as these
latter parameters are an element of the stratification of
patients in the new CWS-2002P protocol [7]. Although
our observations are similar to those reported by other
authors, who had also stressed the importance of tumour
localization and disease stage as the most important
predictive values [11-13], yet some differences do meet
the eye. Raney et al. [11] have reported the region of the
head and neck, as well as the extremities, as the more
favourable tumour locations. Zogopoulos et al. [13] have
reported that tumours localized within the extremities
had had the best prognosis, while in our study tumours
located on the extremities had the worst outcome.
Moreover, in the study of Zogopoulos et al. [13] patients
with primary pelvic tumours achieved very poor survival,
while in the case of our study material this group had the
most favourable outcome. Although our group is
relatively small, this observation may suggest that our
patients had, in fact, represented another population of
children. Additionally, although Zogopoulos et al. have
identified gender as a significant prognostic parameter,
longer survivals characterised the boys (boys vs. girls
survival ratio: 78.5% vs. 52.1%; p=0.007). In our group,
boys had a less favorable outcome and we have failed to
find any explanation for this discrepancy. As has already
been demonstrated [17], we have confirmed that there
were no significant differences in survival between EES
and PNET.
The cooperation of Polish centres for paediatric
oncology has resulted in the unification of the treatment
modalities applied in the case of soft tissue sarcomas in
children. A significant improvement in survival was noted
after the introduction of new protocol – the CWS-96. We
do hope, that new CWS-2002P protocol [7] will result in
further improvement of prognosis in Polish children
suffering from EES or PNET. The introduction of
maintenance chemotherapy after intensive chemotherapy,
which the CWS-96 protocol provides for patients with
distant metastases, could further improve survival in
patients with PNET and EES. This may be supported by
the results obtained in IRS groups [11], where a majority
of patients are treated for a long period of time (81% of
individuals were treated for 2 years). Moreover, the
introduction of a new treatment option could further
improve patient prognosis [18-20].
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